Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients

Table 1 Data on EOC BM patients

Characteristics	Risk factor	Mean	SD	Median	Q1	Q3	Min.	Max.
Age	at EOC diagnosis	52.6	9.3	54	47	59.3	27	67
	at SRT	56.3	9.2	56.5	50.8	62	35	77
Clinical	CA125 before CT1 [U/mL]	1578	2317	740	151	1946	19	9693
	CA125 after CT1 [U/mL]	29	69	13	8	17	2	318
	CA125 before CT2 [U/mL]	566	791	190	84	690	38	2407
	CA125 after CT2 [U/mL]	73	143	22	10	57	9	496
	CA125 before SRT [U/mL]	132	189	56	25	139	8	533
	ZUBROD	1.2	0.4	1	1	1	1	3
	FIGO			IIIC	IIIA	IIIC	IA	IVA
	Tumor grade [G]	2.6	0.5	3	2	3	2	3
	Histopathology:	adenocarcinoma serosum = 53%, adenocarcinoma endometroides = 25%, cystadenocarcinoma mucinosum = 6%, non-differentiated = 13%, not examined = 3%
Imaging	No. of BMs at diagnosis	1.8	0.8	2	1	2	1	3
	Total PTV at diagnosis [cm³]	9.7	14.8	5.1	1.6	10.0	0.4	62.1
	Relapse out of CNS	47%
	Localisation	supratentorial = 25%, infratentorial = 63%, supratentorial/infratentorial = 12%
Treatment	from EOC diagnosis to CT1 [weeks]	6.6	5.9	5	3	8	0	28
	CT1 duration [weeks]	19.6	5.6	18	17	20	12	38
	CT2 duration [weeks]	8.5	10.4	0	0	17	0	34
	Total CT duration (CT1 + CT2) [weeks]	27.7	13	23	18	35	12	72
	No. of CT1 cycles	6.1	0.8	6	6	6	5	9
	No. of CT2 cycles	2.4	2.9	0	0	5.5	0	9
	Total no. of CT cycles (CT1 + CT2)	8.5	3.2	6	6	11.5	5	18
	Surgery	22%
	WBRT before SRT	53%
	WBRT after SRT	16%
	BM to SRT [months]	22	26.9	8	4.8	36	1	117
	BM to SRT (above 1 month)	75%
Follow-up outcome	from EOC diagnosis to BM [months]			29.5(CI95% = 25–44)
	from BM to death [months]			16(CI95% = 8–21)
	from SRS to death [months]			7(CI95% = 6–18)
	from EOC diagnosis to death [months]			49(CI95% = 45–69)
	Deaths during observation	94%

ISSN: 1757-2215